DuPont De Nemours Company Overview

As of August 14, 2026, DuPont de Nemours, Inc. is a Delaware-incorporated, publicly traded advanced-solutions company headquartered in Wilmington and listed on the New York Stock Exchange as DD. Its current boundary excludes Qnity Electronics, spun off in November 2025, and the Aramids business, sold in April 2026. DuPont now concentrates on healthcare, water, construction, aerospace, automotive, and other industrial applications through Healthcare & Water Technologies and Diversified Industrials. The company earns primarily by selling specialized materials, components, filtration technologies, packaging, adhesives, building products, and related application solutions, using direct sales plus distributors and other intermediaries. Its stated purpose centers on essential innovation; control rests with public shareholders through a one-share, one-vote structure and an oversight board, while CEO Lori Koch leads execution. Current growth depends on organic demand, innovation, bolt-on acquisitions, productivity, and disciplined portfolio management. The core capability is application-driven materials science; material constraints include global supply chains, regulation, legacy PFAS obligations, trade frictions, and transition arrangements with separated businesses. These boundaries and current metrics are supported by DuPont's August 2026 filing and 2025 Form 10-K.

DuPont combines a two-century industrial legacy with a much newer legal entity. E.I. du Pont founded the legacy enterprise in 1802, while today's DuPont de Nemours, Inc. was formed in Delaware in 2015 as DowDuPont and reached its current specialty-products lineage through mergers, spin-offs, and divestitures.

The distinction matters because “founded in 1802” describes the heritage business, not the incorporation date of the present public corporation. DuPont's official history identifies E.I. du Pont and the Brandywine gunpowder operation; the 2025 Form 10-K identifies the 2015 corporation and subsequent transformations.

Milestones are supported by DuPont's 1802 history, annual filing, Qnity completion release, and Aramids completion release.

Why does the legal boundary matter?

DuPont's brand heritage spans more than two centuries, but the present issuer is the 2015 DowDuPont corporation after multiple distributions and portfolio exits. That boundary prevents historical achievements, liabilities, products, and revenues from being attributed automatically to today's company.

• Legacy founder: E.I. du Pont in 1802.
• Current issuer formed in Delaware in 2015.
• Dow and Corteva became separate companies in 2019.
• Qnity is independent from November 2025.
• Aramids was classified outside continuing operations before its 2026 sale.

The entity boundary follows the SEC corporate history and DuPont's Aramids closing notice.

DuPont officially frames its purpose around empowering the world with essential innovations to thrive. Its current materials separately label four core values and express long-term direction through customer-centered innovation, a focused growth strategy, and 2035 sustainability goals rather than through a separately branded corporate vision statement.

The purpose is not simply a slogan in the company's public positioning. DuPont links it to solving difficult water, healthcare, construction, mobility, and industrial problems, while its current core values specify four behavioral expectations: put safety and respect first; act with integrity and accountability; grow and improve every day; and solve problems for customers. Current careers materials repeat the purpose language in the context of employee work and innovation.

Strategy and operating choices provide evidence of how the purpose is translated into action. The retained portfolio emphasizes clean-water technologies, medical packaging and devices, energy-efficient building materials, and high-performance industrial applications. In April 2026, DuPont also announced 2035 sustainability goals organized around Sustainable Innovation, Resilient Operations, People, Partners and Communities, and Strong Governance.

There is also a necessary qualification: purpose and sustainability goals are company claims and management commitments, not proof that every product or operating outcome achieves those aspirations. The evidence-led reading is therefore to connect them to observable portfolio choices, customer problem-solving practices, governance systems, and measurable operating progress without treating the statements themselves as outcomes.

Purpose language appears in current DuPont careers materials; strategic positioning appears on the company overview.

The November 2025 separation of Qnity Electronics and April 2026 sale of Aramids changed both what DuPont owns and how its performance should be interpreted. They removed major electronics and protective-fiber businesses from continuing operations, leaving a smaller portfolio centered on healthcare, water, building, and diversified industrial technologies.

Qnity was separated as an independent public company through a distribution to DuPont shareholders. The transaction also created continuing agreements covering areas such as tax, employees, transition services, intellectual property, and legacy liabilities. That means legal separation does not imply the absence of all operational or contractual connections; DuPont's filings describe transition-service and site arrangements that extend beyond the separation date.

The Aramids transaction transferred Kevlar and Nomex operations to Arclin, a TJC portfolio company. DuPont received approximately $1.2 billion of pretax cash proceeds, a $300 million note receivable, and a non-controlling equity interest in Arclin valued at $325 million at closing, expected to represent about 16%. The retained stake is an investment interest, not control of the divested operating business.

What changed after Qnity?

Electronics became an independent public company, so semiconductor and interconnect results moved outside DuPont continuing operations while defined transition, tax, intellectual-property, and legacy-liability arrangements remained between the companies.

What changed after Aramids?

Kevlar and Nomex operations moved to Arclin. DuPont received cash, a note, and a minority equity interest, preserving economic exposure without retaining day-to-day operating control.

Transaction status, continuing-operations treatment, consideration, and transition arrangements are supported by DuPont's Q2 2026 separation disclosures.

This transformation also explains why historical DuPont revenue series must be handled carefully. The 2025 financial statements recast continuing operations as if the Mobility & Materials divestitures, Aramids divestiture, and Electronics separation had occurred from the start of the comparable periods. For current analysis, that recast basis is more decision-useful than mixing old portfolio totals with today's company.

DuPont is owned by its public shareholders, not by its exchange, board, chief executive, or legacy founding family. At the March 30, 2026 proxy record date, each common share carried one vote. Shareholders elect directors; the board oversees corporate policy and management; appointed executives run operations.

DuPont's April 2026 proxy reported a broad shareholder base and identified holders above its disclosure threshold, but one major institutional ownership disclosure was already affected by Vanguard's March 2026 internal realignment. That makes a static “largest owner today” ranking less reliable for an August 2026 page than the underlying control architecture. The later 1-for-3 reverse stock split, effective June 24, reduced share counts proportionally and did not by itself transfer corporate control.

Who holds the economic rights?

Public shareholders hold DuPont common equity and participate economically through their shares. The proxy's one-share, one-vote rule ties ordinary voting power to common-stock ownership rather than to management office.

Who exercises corporate oversight?

The board sets broad policy, appoints officers, assigns management responsibility, and reviews performance. Management executes strategy; the board's oversight role is distinct from operating ownership or day-to-day control.

Ownership and voting mechanics are in the 2026 proxy statement; the split became effective under DuPont's reverse-split announcement.

Governance is structured to create an independent counterweight where board leadership is not fully independent. The 2026 proxy states that all directors other than Edward Breen and Lori Koch were independent under the relevant standards at that time. Because Breen serves as non-executive chair but is not independent, the independent directors appointed Alexander Cutler as Lead Director, with authority over executive sessions, agendas, information flow, and communication with major shareholders.

DuPont creates value by combining proprietary materials, application engineering, specialized manufacturing, recognized brands, and customer qualification support. It sells through two reporting segments: Healthcare & Water Technologies and Diversified Industrials. Revenue comes mainly from commercial sales of products, components, materials, filtration technologies, and associated solutions to industrial and institutional customers.

Healthcare & Water Technologies includes medical packaging, medical-device components, biopharma solutions, protective garments, ion-exchange resins, reverse-osmosis and nanofiltration membranes, and ultrafiltration systems. Representative brands include Tyvek medical packaging and garments, Tychem protective apparel, AmberLite ion-exchange resins, FilmTec membranes, and inge and Integratec ultrafiltration technologies. DuPont describes these as application-intensive offerings for regulated or mission-critical uses.

Diversified Industrials combines building technologies and industrial technologies. Its portfolio includes Tyvek building envelopes, Styrofoam insulation, Corian surfaces, Vespel high-performance parts, Molykote lubricants, Betaforce and Betaseal adhesives, and Cyrel flexographic printing systems. The economic logic is specialization: customers pay for material performance, process reliability, qualification, technical support, and the ability to solve high-cost-of-failure problems.

The value-flow interpretation is grounded in DuPont's descriptions of segment capabilities and distribution and its customer-facing portfolio.

Costs are correspondingly manufacturing- and capability-heavy. The 2025 filing shows cost of sales as the largest disclosed segment expense, alongside selling, general and administrative expense and research and development. Inputs include raw materials, energy, third-party manufacturing and services, intellectual property, specialized sites, technical talent, and working capital. Profit therefore depends on volume, price and mix, productivity, plant reliability, procurement, and effective commercialization of innovation.

DuPont is primarily a business-to-business supplier whose users, specifiers, buyers, and beneficiaries can be different people. Engineers and technical teams often choose or qualify a material; procurement or project owners pay; distributors can intermediate access; and end patients, plant operators, vehicle users, printers, builders, or occupants ultimately experience the outcome.

The company reaches customers mainly through its own sales organization, supplemented in selected product lines by distributors, independent retailers, cooperatives, and agents. Its marketing is consequently technical and application-led rather than purely consumer advertising: recognized brands, technical literature, testing, application development, specification support, and customer problem-solving help create preference before the formal purchasing decision.

Retention is strongest when DuPont becomes embedded in a customer's specification, qualification, manufacturing process, or regulatory documentation. The company does not publish a single corporate retention rate, so the more defensible evidence is operational: technical support, product testing, application development, recognized brands, and local service help preserve repeat business. In regulated or high-cost-of-failure applications, requalification effort can also make supplier changes more consequential.

Seasonality is market-specific rather than company-wide. Building Technologies demand in North America is typically stronger in the second and third quarters, while medical, water, aerospace, automotive, and industrial end markets follow different cycles. That diversity reduces reliance on one customer journey, but it also requires differentiated sales coverage, inventory planning, and commercial expertise.

DuPont remains globally diversified, but the United States is its largest disclosed revenue geography. On the recast 2025 continuing-operations basis, U.S. customer-location revenue was $3.188 billion, followed by Asia Pacific at $1.640 billion and EMEA at $1.468 billion, with smaller contributions from Latin America and Canada.

Geographic revenue is reported by customer location, not necessarily by factory location or legal entity. That distinction matters for interpreting exposure: sales demand can sit in one region while production, raw-material sourcing, intellectual property, or logistics are located elsewhere. At December 31, 2025, before the April 2026 Aramids closing, DuPont reported subsidiaries in about 50 countries and manufacturing operations in about 20.

The geographic mix is strategically useful because DuPont's growth markets are themselves global. Water scarcity, medical-device demand, construction cycles, aerospace production, electric-vehicle applications, and industrial investment vary by region. The same diversity also creates foreign-exchange, geopolitical, tariff, export-control, logistics, and local-regulatory exposure, so geographic breadth is both a growth asset and an execution constraint.

DuPont does not face one clean corporate-wide peer because its portfolio spans several buyer decisions. Competition is better defined by application: Toray overlaps in water membranes, Owens Corning and Saint-Gobain in building materials, Henkel in industrial bonding and sealing, and 3M in selected medical and protective-material categories.

DuPont itself says competition depends on innovation, technology, sustainable practices, pricing, customer service, and regulation, and includes both multinational and regional firms. The table therefore compares overlapping buying contexts rather than implying that each alternative matches DuPont's full portfolio, economics, geographic footprint, or reporting structure.

Substitutes can be broader than named competitors. A customer may redesign an application, change a material class, alter a filtration process, integrate a component internally, or select a lower-performance material when the cost-benefit trade-off permits. DuPont's defense is therefore not simply brand awareness; it is the combination of verified performance, technical integration, customer support, supply reliability, and continuing innovation around the application.

DuPont's current growth model combines organic demand in priority end markets, innovation and commercial execution, selected acquisitions, productivity, and capital allocation. Its September 2025 framework set medium-term targets through 2028, while the August 2026 earnings update provided separate current-year guidance and evidence of recent operating progress.

Growth engines and acquisition history are described in DuPont's value-creation framework and 2025 annual filing.

The 2028 framework is explicitly forward-looking: DuPont targeted 3% to 4% organic sales compound annual growth, 150 to 200 basis points of operating EBITDA margin expansion, 8% to 10% adjusted EPS compound annual growth, and free-cash-flow conversion above 90%. Those are management targets, not achieved historical results.

Actual second-quarter 2026 performance was more immediate: continuing-operations sales rose 4% year over year, organic sales rose 4%, operating EBITDA increased 6%, and management raised full-year guidance. Healthcare & Water Technologies posted 4% organic growth, while Diversified Industrials posted 3%; aerospace and electric-vehicle applications were cited among industrial strengths. The Q2 2026 earnings exhibit also raised expected full-year organic growth to slightly above 4%.

Growth is therefore not one bet. It requires DuPont to protect high-value incumbencies while expanding newer applications, integrate acquisitions without diluting returns, convert research into qualified products, and maintain cost discipline. The portfolio exits make that execution more visible because fewer unrelated businesses remain to offset a weak segment or end market.

CEO Lori Koch is DuPont's top operating authority, serving since June 1, 2024. The current model separates executive management from board leadership: Edward Breen is non-executive chair, Alexander Cutler is independent Lead Director, Antonella Franzen is CFO, and the two segment presidents lead the core operating businesses.

Koch joined DuPont in 2003 and served as CFO before becoming CEO, giving her direct experience in finance, portfolio reshaping, and corporate planning. Her official biography says she oversees strategic direction to accelerate growth, unlock value, advance innovation, and drive operational and functional excellence. That makes her accountable for enterprise execution, while the board retains oversight and appointment authority.

The leadership transition also marks a shift in governance posture. Breen moved from executive chairman to non-executive chairman on November 1, 2025, while Koch remained CEO of the focused company. The board's independent-lead-director structure is significant because it gives independent directors a formal mechanism to run executive sessions, shape agendas, and act as a contact point for major shareholders.

Below the named executives, capability leadership is also material. DuPont's current team includes a chief technology officer, chief operations and engineering officer, chief strategy and M&A officer, chief information officer, general counsel, and chief human resources officer. That functional structure matches the company's current priorities: innovation, manufacturing reliability, portfolio development, digital systems, compliance, and organizational execution.

DuPont's focused portfolio still depends on complex global supply chains, customer capital cycles and qualifications, regulatory compliance, reliable manufacturing, trade access, and management execution. It also carries legacy and separation-related obligations, including PFAS cost-sharing arrangements and continuing contractual links with Qnity and divested businesses.

Dependencies are documented in DuPont's 2025 risk factors and Q2 2026 disclosures.

Customer concentration risk is more nuanced than a single disclosed dependency. DuPont sells into several end markets, but individual product lines can rely on qualification cycles, OEM programs, construction activity, semiconductor-linked water demand, or industrial capital spending. A customer slowdown can therefore affect a niche even when consolidated demand remains healthy. The company's broad application set diversifies that risk without eliminating it.

Technology is another dependency. Roughly 4,700 patents and patent applications were associated with continuing operations at December 31, 2025, and more than 70% of that estate had over five years of remaining term. Patents protect parts of the advantage, but commercialization also depends on know-how, manufacturing consistency, customer trust, brands, talent, and the ability to keep innovating as alternatives improve.

Finally, portfolio focus raises execution stakes. The same simplification that can make capital allocation and accountability clearer also reduces the cushioning effect of businesses that have been spun or sold. DuPont must now make the retained healthcare, water, construction, and industrial franchises carry more of the growth, margin, and cash-generation case on their own.

DuPont today is best understood as a focused, publicly owned advanced-materials and technology company whose identity is shaped by portfolio simplification, application-specific innovation, and technical customer integration. Its opportunity is to convert specialized science into repeatable growth; its test is whether the smaller portfolio can sustain execution across demanding global markets.

What makes the portfolio coherent?

Healthcare, water, building, and industrial businesses differ by customer, but they share an emphasis on engineered performance, application know-how, specialized manufacturing, qualification support, and branded technology.

Where does DuPont earn trust?

The strongest customer relationships arise where material performance, reliability, regulatory confidence, technical service, and continuity of supply matter enough that the supplier becomes part of the customer's process.

What must execution prove?

Management must turn portfolio focus into sustained organic growth, margin discipline, cash conversion, and innovation while absorbing supply, regulatory, trade, and legacy-liability pressures without weakening customer delivery.

This synthesis connects the current portfolio and operating evidence in DuPont's 2025 Form 10-K, Q2 2026 results, and value-creation strategy.